Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that PRISTIQTM (desvenlafaxine), a new serotonin-norepinephrine reuptake inhibitor (SNRI) approved to treat adult patients with major depressive disorder (MDD), is now available in U.S. retail pharmacies nationwide. The recommended dose of PRISTIQ is 50 milligrams (mg) once daily. The Company begins full-scale selling and educational efforts regarding PRISTIQ for physicians this week.
Popularity: unranked [?]
Related posts:
- FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder
- New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms Of Major Depressive Disorder Versus Placebo
- New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms Of Major Depressive Disorder Versus Placebo
- Wyeth Europa Ltd Withdraws Its Marketing Authorisation Application For Ellefore For Major Depressive Disorder
- Wyeth Europa Ltd Withdraws Its Marketing Authorisation Application For Ellefore For Major Depressive Disorder
Comments
No Responses to “Wyeth’s Pristiq, A New Treatment For Major Depressive Disorder”